Description
Tirza (Tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, a once-weekly subcutaneous injectable twincretin that simultaneously activates the GIP receptor (GIPR) with potency comparable to native GIP and the GLP-1 receptor (GLP-1R) to potentiate glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release from pancreatic alpha cells, slow gastric emptying to attenuate postprandial glucose excursions, and engage central satiety circuits in the hypothalamus, producing clinically meaningful reductions in both HbA1c and body weight that exceed those of any previously approved incretin-based agent.
Supplied as a subcutaneous injection in a pre-filled syringe or pen, 1 pre-filled syringe per box, available in strengths of 2.5 mg, 5 mg, and 7.5 mg, and manufactured by Beacon Pharmaceuticals, Bangladesh. Its active ingredient, tirzepatide INN, is a 39-amino acid acylated peptide with structural homology to native GIP, engineered to bind and activate both GIPR and GLP-1R within a single molecular entity, the first approved dual incretin receptor agonist (twincretin) in the antidiabetic drug class, structurally and mechanistically distinct from monoagonist GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) that activate only the GLP-1 receptor.
The co-activation of GIPR by tirzepatide augments the GLP-1R-mediated glycemic and weight effects by engaging adipose tissue GIP receptors involved in lipid partitioning and by potentiating pancreatic beta cell responsiveness through synergistic cyclic adenosine monophosphate (cAMP) signaling from both receptor pathways simultaneously. In the pivotal SURPASS-1 monotherapy trial (478 patients, 40 weeks), tirzepatide 5 mg achieved a mean HbA1c reduction of 1.87% from baseline versus 0.04% with placebo, with 87.4% of patients achieving HbA1c below 7.0% versus 19.9% with placebo, without hypoglycemia as monotherapy; tirzepatide at the 7.5 mg step delivers incrementally greater HbA1c and body weight reductions for patients requiring additional glycemic control.
In the SURPASS-2 head-to-head trial versus semaglutide 1 mg (1,879 patients, 40 weeks), tirzepatide demonstrated statistically significant superiority in both HbA1c reduction and body weight reduction at all doses studied, establishing tirzepatide as the most efficacious approved injectable antidiabetic agent studied against an active comparator in a prospective randomized trial. Searching for Tirza Tirzepatide? Mediaid Pharmacy lists this product across its diabetes medicines and Tirzepatide Medicines portfolios and ships it worldwide.
Basic Product Information of Tirza (Tirzepatide)
| Brand Name | Tirza (Tirzepatide) |
| Product Name | Tirza |
| Generic Name | Tirzepatide INN |
| Drug Class | Dual GIP/GLP-1 Receptor Agonist; Twincretin; Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist; Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist; Dual Incretin Receptor Agonist; Once-Weekly Subcutaneous Injectable Antidiabetic Agent; Incretin Mimetic; Glucose-Dependent Insulin Secretion Potentiator; Glucagon Suppressor; Cardiometabolic Agent; Antiobesity Agent (Adjunct in T2DM) |
| Formulation | Subcutaneous Injection (Pre-filled Syringe / Pen) |
| Available Strengths | 2.5 mg, 5 mg, and 7.5 mg tirzepatide per pre-filled syringe or pen |
| Available Pack Size | 1 pre-filled syringe per box |
| Recommended Dose & Administration | Initiation dose: 2.5 mg subcutaneously once weekly for 4 weeks. This is a tolerability initiation dose, not the therapeutic maintenance dose; it minimizes nausea and gastrointestinal adverse effects during treatment commencement. Step 1 (therapeutic): Increase to 5 mg subcutaneously once weekly after completing 4 weeks at 2.5 mg. Step 2 (if additional glycemic control is required): If adequate glycemic control is not achieved after at least 4 weeks at 5 mg, increase to 7.5 mg subcutaneously once weekly, the maximum strength available in Tirza pre-filled syringes and pens. Injection sites: Administer subcutaneously into the abdomen (at least 5 cm from the navel), thigh, or upper arm; rotate injection sites with each weekly dose to reduce local injection site reactions. Tirza may be injected at any time of day, with or without food. Missed dose: If a dose is missed and the next scheduled dose is more than 4 days away, administer the missed dose as soon as possible and resume the regular weekly schedule. If the next scheduled dose is 4 days or fewer away, skip the missed dose and continue with the next scheduled weekly injection. Do not administer two doses within 3 days of each other. Renal and hepatic impairment: No dose adjustment is required for mild to moderate renal impairment (eGFR 30 mL/min/1.73 m2 or greater); use with caution in severe renal impairment. No dose adjustment required for hepatic impairment. Always confirm the dose, injection technique, and escalation schedule with the prescribing endocrinologist before initiating or adjusting Tirza therapy. |
| Primary Indications | Type 2 Diabetes Mellitus (T2DM): As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, used as monotherapy or in combination with other antidiabetic agents (metformin, sulfonylurea, SGLT2 inhibitor) or basal insulin when existing therapy does not achieve adequate glycemic control. Tirzepatide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Each treatment decision must account for baseline HbA1c, body weight goals, cardiovascular risk, concomitant antidiabetic medications, renal function, and gastrointestinal tolerability. Always consult the full prescribing information and the treating endocrinologist or diabetologist before initiating or adjusting Tirza therapy. |
| Manufacturer | Beacon Pharmaceuticals, Bangladesh |
| Country of Origin | Bangladesh |
| SKU | tirzepatide-tirza |
| Registration | Bangladesh |
| Originator Reference Brand | Mounjaro® (tirzepatide injection, developed and marketed by Eli Lilly and Company; approved by the U.S. Food and Drug Administration on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus). Mounjaro® contains tirzepatide INN as the active pharmaceutical ingredient in the same dual GIP/GLP-1 receptor agonist (twincretin) drug class. Tirza is manufactured by Beacon Pharmaceuticals in Bangladesh and is supplied through Mediaid Pharmacy for international procurement. |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze; discard Tirza pre-filled syringes or pens that have been frozen. If necessary, each pre-filled device may be stored unrefrigerated at room temperature up to 30°C (86°F) for a maximum of 21 days. Protect from light and direct heat. Keep in the original packaging until use. Keep out of the reach of children. Do not use after the expiry date printed on the carton and pre-filled syringe or pen label. |
How Tirza (Tirzepatide) Works: Dual GIP and GLP-1 Receptor Agonism and Twincretin Pharmacology in Type 2 Diabetes
Tirzepatide INN is a 39-amino acid acylated peptide that functions as a dual agonist at two distinct incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). This dual receptor mechanism, the first of its kind among approved antidiabetic agents, earns tirzepatide the designation “twincretin.” Tirza (Tirzepatide) simultaneously activates two complementary glucose-lowering and weight-reducing signaling pathways that monoagonist GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) cannot replicate within a single injection.
GLP-1 is secreted by intestinal L cells in the distal ileum and colon following nutrient ingestion, stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion from pancreatic alpha cells, slowing gastric emptying to reduce postprandial glucose excursions, and activating hypothalamic and brainstem satiety circuits. GIP is secreted by K cells in the duodenum and proximal jejunum in response to fat and carbohydrate ingestion, potentiating glucose-dependent insulin secretion through a distinct cAMP signaling cascade in pancreatic beta cells and engaging adipose tissue GIPR-expressing cells involved in lipid partitioning and energy balance.
In type 2 diabetes mellitus (T2DM), both incretin axes are functionally impaired: the GLP-1 response is markedly attenuated and the residual GIP response fails to elicit a normal insulin secretory response in the insulin-resistant beta cell. This is precisely the dual incretin deficit that tirzepatide’s co-receptor engagement addresses by simultaneously reconstituting both GIP and GLP-1 signaling arms within a single molecular entity administered once weekly.
The structural basis of tirzepatide’s dual receptor activity lies in its peptide architecture: a 39-amino acid sequence with structural homology to native GIP at the N-terminus, optimized through amino acid substitutions for balanced GIPR and GLP-1R binding affinity, conjugated at lysine-26 to a C20 fatty diacid moiety via a gamma-glutamic acid-miniPEG linker. This modification confers high albumin binding exceeding 99%, protects the peptide from N-terminal DPP-4 cleavage that inactivates native GIP and GLP-1 within 1 to 2 minutes of portal entry, and provides an extended elimination half-life of approximately 5 days that supports once-weekly subcutaneous dosing from the 2.5 mg initiation step through the 5 mg and 7.5 mg therapeutic escalation steps available in Tirza.
Tirzepatide activates GIPR with potency approximately equivalent to native GIP and activates GLP-1R with approximately 5-fold lower potency than native GLP-1, yet produces GLP-1R-mediated pharmacological effects (insulin secretion, glucagon suppression, gastric emptying delay, appetite suppression, body weight reduction) that equal or exceed those of optimized GLP-1 monoagonists in head-to-head clinical trials. These superior outcomes are driven by receptor co-stimulation synergy, adipose tissue GIPR contributions to energy balance, and tissue-level interactions between the two simultaneously activated signaling pathways.
Pharmacokinetically, following subcutaneous administration via the pre-filled syringe or pen, tirzepatide reaches peak plasma concentration (Tmax) at approximately 8 to 72 hours, achieves steady-state concentrations by 4 weeks of once-weekly dosing, and is eliminated primarily via proteolytic degradation of the peptide backbone and fatty acid beta-oxidation, with no single dominant cytochrome P450 (CYP) metabolic pathway and no clinically relevant accumulation with weekly dosing across a broad range of renal and hepatic function. The three-step dose titration architecture of Tirza (2.5 mg initiation, 5 mg therapeutic, 7.5 mg intensification) allows the prescribing endocrinologist to individually optimize the balance between glycemic efficacy, weight-reduction benefit, and gastrointestinal tolerability for each patient without requiring a formulation change. For the complete range of diabetes medicines at Mediaid Pharmacy, browse the full portfolio for worldwide shipping.
Tirza (Tirzepatide): Indications, Dosing, and Key Safety Information
| Approved Indications | Type 2 Diabetes Mellitus (T2DM): Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Tirza (Tirzepatide) is used as monotherapy when other oral agents are not tolerated or are contraindicated, and as add-on combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when single-agent or existing combination therapy fails to achieve adequate HbA1c targets. Tirzepatide is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis. The treating endocrinologist determines appropriate candidacy, dose titration schedule across the 2.5 mg, 5 mg, and 7.5 mg steps, and combination regimen based on individual patient HbA1c targets, weight goals, cardiovascular risk, renal function, and gastrointestinal tolerability profile. |
| Dosing Schedule | Week 1 to 4 (Initiation): 2.5 mg subcutaneously once weekly, a tolerability initiation dose and not the therapeutic maintenance dose. Week 5 onward (Step 1 Therapeutic): 5 mg subcutaneously once weekly. After at least 4 weeks at 5 mg (Step 2, if needed): 7.5 mg subcutaneously once weekly, the maximum strength available in Tirza pre-filled syringes and pens. Inject subcutaneously into the abdomen, thigh, or upper arm; rotate injection sites each week. Administer at any time of day, with or without meals. |
| Common Adverse Reactions | The most commonly reported adverse reactions with tirzepatide in the SURPASS Phase 3 clinical trial program are gastrointestinal: nausea (12 to 18% at 5 mg, increasing modestly with dose escalation to 7.5 mg), diarrhea (12 to 17%), vomiting (5 to 11%), and constipation (6 to 11%), predominantly occurring during dose initiation and escalation phases and generally transient in nature. The 2.5 mg initiation dose protocol across the first 4 weeks is specifically designed to reduce the frequency and severity of these gastrointestinal effects before advancing to the 5 mg therapeutic dose. Injection site reactions (erythema, pain, bruising) are reported in approximately 3 to 7% of patients; weekly site rotation minimizes their incidence. Hypoglycemia does not occur with Tirza as monotherapy due to its strictly glucose-dependent insulin secretion mechanism; hypoglycemia risk increases when tirzepatide is combined with a sulfonylurea or basal insulin, and dose reduction of the sulfonylurea or insulin should be considered at initiation. Rare serious adverse reactions include acute pancreatitis (discontinue Tirza immediately if suspected), severe hypersensitivity reactions including anaphylaxis and angioedema, and acute gallbladder disease (cholelithiasis, cholecystitis). Tirza (Tirzepatide) carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Always discuss the complete safety profile with the treating endocrinologist before initiating or continuing Tirza therapy. |
| Drug Interactions | Oral medications requiring rapid absorption or with narrow therapeutic index: Tirzepatide delays gastric emptying and may reduce the peak plasma concentration (Cmax) and alter the time to peak concentration (Tmax) of concomitantly administered oral medications. Particular caution is warranted with narrow therapeutic index oral drugs such as warfarin, cyclosporine, and digoxin. Oral contraceptives: When initiating Tirza or escalating the dose at each step (2.5 mg to 5 mg, or 5 mg to 7.5 mg), gastric emptying delay may transiently reduce peak concentrations of oral contraceptives; switch to non-oral contraception or add a barrier method for 4 weeks after starting Tirza and for 4 weeks after each dose escalation step. Warfarin and other vitamin K antagonists: Monitor INR more frequently when initiating or dose-escalating Tirza due to the potential effect on warfarin absorption kinetics. Insulin secretagogues and basal insulin: Concomitant use with a sulfonylurea (glimepiride, glibenclamide) or basal insulin (insulin glargine, insulin detemir) increases hypoglycemia risk; consider reducing the sulfonylurea or insulin dose when adding Tirza to existing antidiabetic therapy. Other GLP-1 receptor agonists: Do not combine Tirza (Tirzepatide) with another GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide, exenatide) as additive receptor agonism provides no established additional glycemic benefit and compounds gastrointestinal adverse effects. |
| Contraindications | Tirza (Tirzepatide) is contraindicated in: patients with a personal or family history of medullary thyroid carcinoma (MTC); patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); patients with known serious hypersensitivity to tirzepatide or any component of the Tirza formulation (including anaphylaxis or angioedema). Tirzepatide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. |
| Renal Impairment | No dose adjustment of Tirza (Tirzepatide) is required for mild to moderate renal impairment (eGFR 30 mL/min/1.73 m2 or greater). Use with caution in severe renal impairment (eGFR less than 30 mL/min/1.73 m2) due to limited clinical data; the predominantly non-renal elimination of tirzepatide means pharmacokinetic exposure is not substantially increased by renal impairment, but gastrointestinal adverse effects (nausea, vomiting, diarrhea) that occur particularly during the 2.5 mg to 5 mg escalation phase may precipitate dehydration and acute kidney injury in renally vulnerable patients, necessitating closer clinical monitoring, hydration counseling, and renal function assessment. Consult the treating endocrinologist and nephrologist for individualized guidance in patients with advanced chronic kidney disease before initiating or escalating Tirza. |
| Pregnancy & Lactation | Tirza (Tirzepatide) is not recommended during pregnancy. Tirzepatide caused adverse embryo-fetal developmental effects in animal reproductive toxicity studies at clinically relevant exposures; adequate and well-controlled human data in pregnancy are not available. The risks of uncontrolled maternal hyperglycemia during pregnancy and of tirzepatide fetal exposure must be carefully weighed; insulin remains the preferred antidiabetic agent during pregnancy for type 2 diabetes mellitus. Women of childbearing potential should use effective contraception throughout Tirza therapy; if pregnancy occurs or is planned, discontinue Tirza and transition to insulin therapy immediately under endocrinologist guidance. Breastfeeding is not recommended during Tirza treatment, as it is unknown whether tirzepatide is excreted in human breast milk; the risk to the nursing infant cannot be excluded. |
Who Should Use Tirza (Tirzepatide)?
Tirza (Tirzepatide) is indicated for adults with type 2 diabetes mellitus requiring improved glycemic control as an adjunct to diet and exercise, a patient population defined by progressive insulin secretory failure, marked GLP-1 and GIP response impairment, postprandial glucagon excess, and frequently co-occurring excess body weight, for whom a once-weekly dual incretin receptor agonist with a three-step dose titration architecture provides simultaneous glycemic and cardiometabolic benefits that are mechanistically unachievable by existing oral antidiabetic classes or monoagonist injectable agents.
First, adults with type 2 diabetes requiring substantial HbA1c reduction represent the primary population where Tirza’s superior efficacy profile is most clinically relevant. Those presenting with baseline HbA1c above 8.5%, or requiring reductions exceeding 1.5% to reach individual targets, benefit most from the twincretin approach combined with Tirza’s stepwise escalation to 7.5 mg. In SURPASS-1 monotherapy (40 weeks, 478 patients), tirzepatide 5 mg achieved 1.87% HbA1c reduction with 87.4% of patients reaching HbA1c below 7.0% versus 0.04% reduction and 19.9% target achievement with placebo; the 7.5 mg step in Tirza allows for incremental HbA1c intensification in patients who require greater glycemic correction than 5 mg achieves after at least 4 weeks of therapy.
Second, adults with type 2 diabetes and significant overweight or obesity for whom concurrent meaningful weight loss is a clinical priority represent an especially important population for Tirza therapy. In SURPASS-2 versus semaglutide 1 mg (40 weeks), tirzepatide at the 5 mg dose produced mean body weight reduction of 7.6 kg versus 5.7 kg with semaglutide 1 mg (p<0.001); escalation to 7.5 mg delivers additional weight reduction benefit for patients with a higher baseline body mass index or greater weight-loss clinical target.
Third, adults with type 2 diabetes requiring injectable antidiabetic therapy escalation beyond oral agents, or those in whom GLP-1 monoagonist therapy has produced suboptimal glycemic or weight outcomes, benefit specifically from tirzepatide’s additional GIPR co-agonism, a mechanistically distinct signaling pathway not activated by semaglutide, liraglutide, or dulaglutide. The availability of the 7.5 mg step in Tirza means clinicians do not need to switch the patient’s formulation to achieve a second-tier dose intensification.
Fourth, adults with type 2 diabetes for whom minimizing hypoglycemia risk is a clinical priority benefit from tirzepatide’s glucose-dependent, insulin-only-when-needed mechanism, which produced no hypoglycemia as monotherapy across all SURPASS studies regardless of dose. Endocrinology centers and diabetes specialist clinics co-sourcing Tirza alongside other specialty injectable antidiabetic medicines can browse the Mediaid Pharmacy injectable diabetes medicines portfolio for the full selection available for international delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Tirza (Tirzepatide)
Mediaid Pharmacy is a Dhaka-based supplier of specialty diabetes, endocrinology, and metabolic medicines with worldwide shipping to patients, diabetes specialist centers, endocrinology clinics, hospital pharmacy departments, and international distributors across all regions. Tirza (Tirzepatide), manufactured by Beacon Pharmaceuticals in Bangladesh, is supplied as a subcutaneous injection in pre-filled syringes and pens, available in 2.5 mg, 5 mg, and 7.5 mg strengths, 1 pre-filled device per box, with pricing quotations, stock confirmation for each strength, full product documentation, and end-to-end international delivery tracking for every order.
The pre-filled syringe and pen formulation of Tirza supports once-weekly self-administration without requiring dose measurement or device assembly, making procurement, dispensing, patient instruction, and injection technique training straightforward for diabetes clinics and endocrinology programs co-sourcing all three dose steps across a single product range from a single supplier. Diabetes specialist centers managing type 2 diabetes requiring superior glycemic and weight-reduction efficacy across a structured three-step dose escalation pathway, endocrinology programs requiring a dual GIP/GLP-1 receptor agonist with the SURPASS Phase 3 clinical evidence base, hospital pharmacy departments co-sourcing injectable antidiabetic agents for inpatient or outpatient use, international distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding Tirza Tirzepatide stock availability, current per-strength pricing, and international delivery timelines.
Procurement teams co-sourcing Tirza with other specialty diabetes or metabolic medicines can browse the complete Mediaid Pharmacy buy diabetes medicines online catalog and the Beacon Pharmaceuticals medicines portfolio before requesting a consolidated quotation.
Why Choose Tirza (Tirzepatide) from Mediaid Pharmacy?
Tirza (Tirzepatide) delivers the most clinically documented HbA1c reduction and body weight reduction among approved injectable antidiabetic agents, a differentiation established in the SURPASS clinical trial program through a unique twincretin mechanism of simultaneous GIP and GLP-1 receptor co-activation that no single-receptor GLP-1 agonist, DPP-4 inhibitor, SGLT2 inhibitor, or insulin class member can replicate in a single weekly injection. In SURPASS-2 (1,879 adults with type 2 diabetes, 40 weeks), all tirzepatide doses demonstrated statistically significant superiority over semaglutide 1 mg in both HbA1c reduction and body weight reduction (p<0.001 for both endpoints), establishing tirzepatide as the first injectable antidiabetic agent to beat the most widely prescribed GLP-1 receptor agonist in a prospective, randomized, active-controlled head-to-head trial. Tirza’s three-strength range (2.5 mg, 5 mg, 7.5 mg) means this clinical superiority data is accessible to patients from the 5 mg first therapeutic dose, with a second escalation step to 7.5 mg available within the same product range without a formulation switch, a procurement advantage for clinics managing patients across the early and mid-range of the tirzepatide dose escalation ladder.
From a tolerability architecture perspective, the mandatory 2.5 mg initiation dose embedded in Tirza’s approved dosing schedule, a 4-week tolerability titration before advancing to the 5 mg therapeutic dose, reduces gastrointestinal adverse event-related treatment discontinuation, with the added benefit that all three doses of Tirza are procurable from a single product range.
The absence of hypoglycemia as monotherapy, a direct consequence of tirzepatide’s strictly glucose-dependent insulin secretion mechanism that automatically extinguishes the insulin secretory signal as plasma glucose normalizes, means Tirza can be initiated across the full escalation sequence (2.5 mg through 7.5 mg) without hypoglycemia dietary restriction protocols beyond standard diabetic care, clinically differentiating it from sulfonylureas and insulin.
From a dosing convenience standpoint, the once-weekly subcutaneous injection via the pre-filled syringe or pen eliminates the daily injection burden of liraglutide and the daily oral medication adherence requirement of DPP-4 inhibitors and SGLT2 inhibitors, supporting high adherence profiles across the dose escalation period.
Tirza, manufactured by Beacon Pharmaceuticals in Bangladesh, delivers the same active pharmaceutical ingredient, tirzepatide INN, in pre-filled devices at the approved subcutaneous injection formulation, sourced through Mediaid Pharmacy with worldwide shipping. To source the full range of Beacon Pharmaceuticals medicines and the complete selection of tirzepatide subcutaneous injection products at Mediaid Pharmacy, browse both portfolios and contact the team for a personalized quotation.
Frequently Asked Questions About Tirza (Tirzepatide)
What is Tirza (Tirzepatide) used for?
Tirza (Tirzepatide) is a dual GIP and GLP-1 receptor agonist, a twincretin, used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Administered once weekly as a subcutaneous injection via a pre-filled syringe or pen, Tirza is used as monotherapy when metformin or other oral agents are not tolerated or are contraindicated, and as add-on combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when existing treatment fails to achieve adequate HbA1c control. Tirza (Tirzepatide) works by simultaneously activating the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release, slowing gastric emptying to reduce postprandial glucose excursions, and engaging central satiety pathways to reduce appetite and body weight, producing clinically superior HbA1c and body weight reductions compared to monoagonist GLP-1 receptor agonists in head-to-head prospective trials. The originator brand for tirzepatide is Mounjaro® (Eli Lilly and Company, FDA-approved May 13, 2022 for adults with T2DM). Tirza, manufactured by Beacon Pharmaceuticals in Bangladesh, is available through Mediaid Pharmacy with worldwide shipping to patients, diabetes specialist centers, and endocrinology clinics globally.
What is the generic name of Tirza?
The generic name of Tirza is tirzepatide INN. Tirza is the brand name registered by Beacon Pharmaceuticals for tirzepatide manufactured in Bangladesh. Tirza is formulated as a subcutaneous injection in pre-filled syringes and pens, available in 2.5 mg, 5 mg, and 7.5 mg strengths, supplied as 1 pre-filled device per box, supporting the approved once-weekly dosing schedule from initiation at 2.5 mg through stepwise dose escalation to 5 mg and then 7.5 mg as directed by the treating endocrinologist. The originator reference brand is Mounjaro® (Eli Lilly and Company). Mediaid Pharmacy distributes Tirza globally with worldwide shipping to patients, diabetes centers, endocrinology clinics, and hospital pharmacy departments.
What is the difference between Tirza (Tirzepatide) and Mounjaro® (Tirzepatide)?
Tirza and Mounjaro® both contain tirzepatide INN as the active pharmaceutical ingredient and share the same dual GIP/GLP-1 receptor agonist (twincretin) mechanism of action for type 2 diabetes mellitus. Mounjaro® is the originator brand developed and marketed by Eli Lilly and Company, approved by the FDA on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Tirza is manufactured by Beacon Pharmaceuticals in Bangladesh and is supplied in pre-filled syringes and pens in 2.5 mg, 5 mg, and 7.5 mg strengths, covering the initiation, first therapeutic, and second therapeutic dose steps corresponding to the first 12 or more weeks of the approved tirzepatide escalation schedule, with 1 pre-filled device per box, available through Mediaid Pharmacy for international procurement by specialist diabetes centers and patients in regions where Mounjaro® may be unavailable or cost-prohibitive. For the full range of buy tirzepatide injection online at Mediaid Pharmacy, browse the complete collection.
How is Tirza (Tirzepatide) administered?
Tirza (Tirzepatide) is administered once weekly as a subcutaneous injection using the pre-filled syringe or pen. Recommended injection sites are the abdomen (at least 5 cm from the navel), the thigh, or the upper arm; rotate injection sites with each weekly administration to minimize local injection site reactions such as erythema, bruising, and pain. Tirza may be administered at any time of day, independently of meals. The approved initiation schedule begins with 2.5 mg once weekly for 4 weeks; after 4 weeks, advance to 5 mg once weekly. If additional glycemic control is required after at least 4 weeks at 5 mg, increase to 7.5 mg once weekly, the maximum strength available in Tirza pre-filled syringes and pens. If a dose is missed and the next scheduled dose is more than 4 days away, administer the missed dose as soon as possible and resume the regular weekly schedule. If the next scheduled dose is 4 days or fewer away, skip the missed dose and continue with the next scheduled weekly injection; never administer two doses within 3 days of each other. Store Tirza pre-filled devices refrigerated at 2°C to 8°C until use. Always confirm injection technique and dose escalation timing with the prescribing endocrinologist before commencing Tirza therapy.
What are the side effects of Tirza (Tirzepatide)?
The most common side effects of Tirza (Tirzepatide) are gastrointestinal: nausea (reported in 12 to 18% of patients at 5 mg, with modest increase at 7.5 mg), diarrhea (12 to 17%), vomiting (5 to 11%), and constipation (6 to 11%), predominantly occurring during dose initiation and escalation and typically transient. The mandatory 2.5 mg initiation dose protocol for the first 4 weeks is specifically designed to reduce the frequency and severity of gastrointestinal adverse effects before advancing to the 5 mg and 7.5 mg therapeutic doses. Injection site reactions (erythema, bruising, pain at the injection site) are reported in approximately 3 to 7% of patients; rotating injection sites each week reduces their incidence. Hypoglycemia does not occur with Tirza as monotherapy due to its glucose-dependent insulin secretion mechanism; hypoglycemia risk increases when Tirza is combined with a sulfonylurea or basal insulin, and dose reduction of those agents should be considered. Rare but serious adverse reactions include acute pancreatitis (discontinue Tirza immediately if pancreatitis is suspected) and severe hypersensitivity reactions including anaphylaxis and angioedema. Tirza carries a boxed warning for thyroid C-cell tumors (medullary thyroid carcinoma observed in rodent studies at clinically relevant exposures); instruct patients to report any neck masses, hoarseness, dysphagia, or persistent dysphonia. Always discuss the full safety profile, thyroid carcinoma family history, contraindications, and combination therapy hypoglycemia risk with the treating endocrinologist before and throughout Tirza treatment.
Does Tirza (Tirzepatide) cause weight loss?
Yes. Tirza (Tirzepatide) produces clinically meaningful and dose-dependent body weight reductions in adults with type 2 diabetes, driven by its dual GIP and GLP-1 receptor agonism acting on hypothalamic satiety circuits to reduce appetite, gastric emptying delay reducing caloric absorption rate, and adipose tissue GIPR engagement modulating energy partitioning. In SURPASS-1 monotherapy (40 weeks), tirzepatide 5 mg produced mean body weight reduction of 7.0 kg versus 0.7 kg with placebo, without dietary intervention beyond standard diet-and-exercise counseling; the 7.5 mg step available in Tirza delivers incrementally greater weight reduction for patients with higher baseline body weight or more ambitious weight-loss clinical targets. In SURPASS-2 versus semaglutide 1 mg (40 weeks, 1,879 patients), tirzepatide 5 mg produced mean weight reduction of 7.6 kg, significantly greater than semaglutide 1 mg at 5.7 kg (p<0.001), with reductions accompanied by significant improvements in waist circumference, systolic blood pressure, triglycerides, and markers of insulin resistance. The treating endocrinologist determines whether Tirza Tirzepatide is the appropriate agent and which dose step (5 mg or 7.5 mg) best balances efficacy and tolerability for the individual patient. For the full range of diabetes medicines at Mediaid Pharmacy available with worldwide shipping, browse the complete portfolio.
How does Tirza (Tirzepatide) compare to semaglutide for type 2 diabetes?
Tirza (Tirzepatide) and semaglutide (originator brand: Ozempic®) are both once-weekly subcutaneous injectable antidiabetic agents, but they act through different receptor mechanisms. Semaglutide is a monoagonist GLP-1 receptor agonist that activates only the GLP-1R. Tirzepatide is a dual GIP/GLP-1 receptor agonist (twincretin) that simultaneously activates both the GIPR and GLP-1R, adding an incretin signaling arm that semaglutide does not engage. In the SURPASS-2 head-to-head trial (1,879 adults with T2DM, 40 weeks), tirzepatide at all doses studied demonstrated statistically significant superiority over semaglutide 1 mg in both HbA1c reduction and body weight reduction (p<0.001 for both endpoints), with tirzepatide 5 mg achieving 1.94% HbA1c reduction and 7.6 kg weight loss versus 1.86% and 5.7 kg with semaglutide 1 mg and 7.5 mg achieving incrementally greater results. This superiority across all doses of tirzepatide versus the most widely prescribed GLP-1 receptor agonist in a randomized, active-controlled trial is the defining clinical differentiation of the twincretin class. The full selection of tirzepatide medicines at Mediaid Pharmacy is available for worldwide shipping; contact the team for per-strength pricing and current stock availability.
What are the available strengths of Tirza Tirzepatide?
Tirza (Tirzepatide) manufactured by Beacon Pharmaceuticals is available in 2.5 mg, 5 mg, and 7.5 mg pre-filled syringes and pens, supplied as 1 pre-filled device per box. The 2.5 mg strength is used for the 4-week tolerability initiation phase; the 5 mg strength is the first therapeutic maintenance dose; and the 7.5 mg strength is the second-step intensification dose for patients requiring additional glycemic and weight-reduction benefit after at least 4 weeks at 5 mg. All three dose steps are available as separate procurable units from Mediaid Pharmacy. For ordering, stock confirmation by strength, and current pricing, contact Mediaid Pharmacy at +8801773428128 or email info@mediaidpharmacy.com.
Can I order Tirza (Tirzepatide) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Beacon Pharmaceuticals Tirza (Tirzepatide) pre-filled syringes and pens, available in 2.5 mg, 5 mg, and 7.5 mg strengths, to patients, diabetes specialist centers, endocrinology clinics, hospital pharmacy departments, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing by strength, current stock availability, and international delivery details for your country.
Order Tirza (Tirzepatide) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.